

1. Babaian A, Rothe K, Girodat D, Minia I, Djondovic S, Milek M, et al. Loss of m1acp3Ψ Ribosomal RNA Modification Is a Major Feature of Cancer. *Cell Rep*. 2020;31:epub.
2. Colorectal cancer statistics - Canadian Cancer Society [Internet]. [www.cancer.ca](http://www.cancer.ca). [cited 2018 Mar 4]. Available from: <http://www.cancer.ca/en/cancer-information/cancer-type/colorectal/statistics/?region=on>
3. Siegel RL, Fedewa SA, Anderson WF, Miller KD, Ma J, Rosenberg PS, et al. Colorectal Cancer Incidence Patterns in the United States, 1974–2013. *JNCI J Natl Cancer Inst* [Internet]. 2017 [cited 2018 Mar 4];109. Available from: <https://academic.oup.com/jnci/article/109/8/djw322/3053481>
4. Consortium IHGS. Finishing the euchromatic sequence of the human genome. *Nature*. 2004;431:931–45.
5. Shi Z, Barna M. Translating the genome in time and space: specialized ribosomes, RNA regulons, and RNA-binding proteins. *Annu Rev Cell Dev Biol*. 2015;31:31–54.
6. Dinman JD. Pathways to Specialized Ribosomes: The Brussels Lecture. *J Mol Biol*. 2016;428:2186–94.
7. Shi Z, Fujii K, Kovary KM, Genuth NR, Röst HL, Teruel MN, et al. Heterogeneous Ribosomes Preferentially Translate Distinct Subpools of mRNAs Genome-wide. *Mol Cell*. 2017;67:71–83.e7.
8. Yadav A, Radhakrishnan A, Panda A, Singh A, Sinha H, Bhanot G. The Modular Adaptive Ribosome. *PLOS ONE*. 2016;11:e0166021.
9. Slavov N, Semrau S, Airoidi E, Budnik B, van Oudenaarden A. Differential Stoichiometry among Core Ribosomal Proteins. *Cell Rep*. 2015;13:865–73.
10. Krogh N, Jansson MD, Häfner SJ, Tehler D, Birkedal U, Christensen-Dalsgaard M, et al. Profiling of 2'-O-Me in human rRNA reveals a subset of fractionally modified positions and provides evidence for ribosome heterogeneity. *Nucleic Acids Res*. 2016;44:7884–95.
11. Jack K, Bellodi C, Landry DM, Niederer RO, Meskauskas A, Musalgaonkar S, et al. rRNA pseudouridylation defects affect ribosomal ligand binding and translational fidelity from yeast to human cells. *Mol Cell*. 2011;44:660–6.
12. Sloan KE, Warda AS, Sharma S, Entian K-D, Lafontaine DLJ, Bohnsack MT. Tuning the ribosome: The influence of rRNA modification on eukaryotic ribosome biogenesis and function. *RNA Biol*. 2017;14:1138–52.
13. Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson MR, et al. The genomic landscape of pediatric and young adult t-lineage acute lymphoblastic leukemia. *Nat Genet*. 2017;49:1211–8.
14. Ljungström V, Cortese D, Young E, Pandzic T, Mansouri L, Plevova K, et al. Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. *Blood*. 2016;127:1007–16.

15. Babaian A. Intra- and Inter-individual genetic variation in human ribosomal RNAs. *bioRxiv*. 2017;118760.
16. Kuo BA, Gonzalez IL, Gillespie DA, Sylvester JE. Human ribosomal RNA variants from a single individual and their expression in different tissues. *Nucleic Acids Res*. 1996;24:4817–24.
17. Sulima SO, Hofman IJF, De Keersmaecker K, Dinman JD. How Ribosomes Translate Cancer. *Cancer Discov*. 2017;7:1069–87.
18. Tan C, Du X. KRAS mutation testing in metastatic colorectal cancer. *World J Gastroenterol WJG*. 2012;18:5171–80.
19. Taoka M, Nobe Y, Yamaki Y, Sato K, Ishikawa H, Izumikawa K, et al. Landscape of the complete RNA chemical modifications in the human 80S ribosome. *Nucleic Acids Res*. 2018;46:9289–98.
20. Helm M, Motorin Y. Detecting RNA modifications in the epitranscriptome: predict and validate. *Nat Rev Genet*. 2017;18:275–91.
21. McCoy LS, Xie Y, Tor Y. Antibiotics that target protein synthesis. *Wiley Interdiscip Rev RNA*. 2011;2:209–32.
22. Natchiar SK, Myasnikov AG, Kratzat H, Hazemann I, Klaholz BP. Visualization of chemical modifications in the human 80S ribosome structure. *Nature*. 2017;551:472–7.
23. Meyer B, Wurm JP, Sharma S, Immer C, Pogoryelov D, Kötter P, et al. Ribosome biogenesis factor Tsr3 is the aminocarboxypropyl transferase responsible for 18S rRNA hypermodification in yeast and humans. *Nucleic Acids Res*. 2016;44:4304–16.
24. Lareau LF, Hite DH, Hogan GJ, Brown PO. Distinct stages of the translation elongation cycle revealed by sequencing ribosome-protected mRNA fragments. *eLife*. 2014;3:e01257.
25. Grentzmann G, Ingram JA, Kelly PJ, Gesteland RF, Atkins JF. A dual-luciferase reporter system for studying recoding signals. *RNA*. 1998;4:479–86.
26. Myasnikov AG, Natchiar SK, Nebout M, Hazemann I, Imbert V, Khatter H, et al. Structure–function insights reveal the human ribosome as a cancer target for antibiotics. *Nat Commun*. 2016;7:12856.
27. Francesco EMD, Bonuccelli G, Maggiolini M, Sotgia F, Lisanti MP, De Francesco EM, et al. Vitamin C and Doxycycline: A synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs). *Oncotarget*. 2017;8:67269–86.
28. Marciano R, Leprivier G, Rotblat B. Puromycin labeling does not allow protein synthesis to be measured in energy-starved cells. *Cell Death Dis*. 2018;9:39.
29. Mortison JD, Schenone M, Myers JA, Zhang Z, Chen L, Ciarlo C, et al. Tetracyclines Modify Translation by Targeting Key Human rRNA Substructures. *Cell Chem Biol*. 2018;25:1506–1518.e13.